CNCure Biotech Co., Ltd. is a pioneering biotech company at the forefront of developing revolutionary bacteria-based cancer immuno-therapy and cutting-edge radiopharmaceuticals. Our focus lies in advancing a two-pronged approach: the Microbial Cancer Therapeutics (MCT) technology and the Theranostics radiopharmaceutical platform. The Microbial Cancer Therapeutics (MCT) technology represents a groundbreaking paradigm in cancer treatment. At its core is our innovative SAM (Salmonella-based Armed Microbe). On the other front, our radiopharmaceutical platform introduces [18F]DMPY2, a promising agent designed for diagnosing malignant melanoma. Having successfully completed pre-clinical trials, [18F]DMPY2 is now poised for clinical trials. Its exceptional specificity positions it as a superior alternative to [18F]FDG, the current clinical standard, boasting heightened detection rates not only for melanoma but also for metastatic lesions.
moreEXHIBIT
DMPY2
DMPY2 is an innovative radiopharmaceutical used for the diagnosis of malignant melanoma. This drug exhibits excellent specificity, allowing for the detection of melanoma and metastatic lesions with high accuracy. Currently, DMPY2 has completed pre-clinical trials and is currently in preparation for clinical trials. To provide precise and rapid diagnosis, it is anticipated to enhance diagnostic accuracy in medical settings and contribute to the early detection of malignant melanoma.
More
SAM-01
SAM-01 is an advanced Salmonella-based Cancer Immunotherapy, engineered to be attenuated for safety. Leveraging the innate motility and chemotaxis of bacteria, SAM-01 exhibits a unique tumor-targeting capability, positioning it at the forefront of next-generation cancer therapies. Furthermore, this innovative approach allows SAM-01 not only to target tumors effectively but also to serve as a potential vehicle for delivering immunoreactive anticancer proteins to the tumor microenvironment.
More
COMPANY INTRODUCTION
CNCure Biotech Co., Ltd. is a pioneering biotech company at the forefront of developing revolutionary bacteria-based cancer immuno-therapy and cutting-edge radiopharmaceuticals. Our focus lies in advancing a two-pronged approach: the Microbial Cancer Therapeutics (MCT) technology and the Theranostics radiopharmaceutical platform. The Microbial Cancer Therapeutics (MCT) technology represents a groundbreaking paradigm in cancer treatment. At its core is our innovative SAM (Salmonella-based Armed Microbe). On the other front, our radiopharmaceutical platform introduces [18F]DMPY2, a promising agent designed for diagnosing malignant melanoma. Having successfully completed pre-clinical trials, [18F]DMPY2 is now poised for clinical trials. Its exceptional specificity positions it as a superior alternative to [18F]FDG, the current clinical standard, boasting heightened detection rates not only for melanoma but also for metastatic lesions.
